Goldman Sachs ActiveBeta International Equity ETF
The Goldman Sachs ActiveBeta International Equity ETF (GSIE) is a sophisticated investment vehicle designed to capture the essence of global equity markets, excluding the U.S., through a dynamic and strategic approach. As a Size and Style-focused ETF, GSIE targets the Total Market, offering investors a comprehensive exposure that spans across various market capitalizations and investment styles. This broad-based niche ETF is meticulously crafted to harness the potential of international markets by employing an ActiveBeta strategy, which seeks to outperform traditional market-cap-weighted indices through advanced factor-based investing. GSIE deploys a multi-factor investment strategy, emphasizing value, momentum, quality, and low volatility, to identify stocks that are poised for long-term growth and stability. By incorporating these factors, the ETF aims to provide a balanced exposure that mitigates risks while capturing upside potential in diverse market conditions. This makes GSIE an appealing choice for investors who are looking to diversify their portfolios with international equities and benefit from the expertise of Goldman Sachs in navigating global market complexities. Furthermore, the ETF's design allows it to adapt to changing market dynamics, offering a more responsive and agile investment option compared to traditional passive index funds. With its focus on a broad market segment and an innovative investment approach, the Goldman Sachs ActiveBeta International Equity ETF stands out as a versatile and intelligent choice for investors seeking to capitalize on international opportunities while maintaining a disciplined and factor-driven investment philosophy.
AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s TREVI-OC-02 study is testing torvutatug samrotecan with bevacizumab as first-line maintenance treatment for advanced ovarian, fallopian
AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s Phase 3 MATTERHORN-CN study is testing treatment for Chinese patients with operable gastric and gastroesophageal junction
| Name | Weight % |
|---|---|
| ASMLASML Holding NV | 1.86% |
| ROPRoche Holding | 1.15% |
| RYRoyal Bank Of Canada | 1.13% |
| NOVNNovartis | 1.08% |
| HSBAHsbc Holdings Plc (UK) | 1.00% |
| AZNAstraZeneca plc | 0.86% |
| TDToronto Dominion Bank | 0.84% |
| 6857Advantest Corp | 0.83% |
| 6098Recruit Holdings Co | 0.81% |
| SHELShell plc (UK) | 0.76% |
| Total | 10.32% |
